Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 1:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,546 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Girls, alone Clear all
Withdrawn Phase 1 Interventional Accepts healthy volunteers

AZD6765 Oral Single Ascending Dose/Multiple Ascending Dose (SAD/MAD)

NCT00963365
View directory record Official record
Conditions
Healthy
Interventions
AZD6765
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 13, 2014 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug-Drug Interaction Study to Evaluate the Effect of Vapendavir on the Pharmacokinetics of Midazolam in Healthy Male and Female Volunteers

NCT02204501
View directory record Official record
Conditions
Drug-Drug Interaction Healthy Volunteers
Interventions
Midazolam 5mg Syrup, Vapendavir 264 mg BID, Vapendavir 528 mg QD
Drug
Lead sponsor
Biota Scientific Management Pty Ltd
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated May 30, 2018 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Short Term Response of Breast Milk Micronutrient Concentrations to a Lipid Based Nutrient Supplement in Guatemalan Women

NCT02464111
View directory record Official record
Conditions
Malnutrition
Interventions
Treatment 1: Control, Treatment 2: Bolus (LNS), Treatment 3: Divided Dose (LNS)
Other · Dietary Supplement
Lead sponsor
USDA, Western Human Nutrition Research Center
Federal
Eligibility
18 Years to 40 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 9, 2015 · Synced Nov 1, 2026, 1:44 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Effects of Estrogen on Heart Health in Women With Primary Ovarian Insufficiency

NCT06866119
View directory record Official record
Conditions
Primary Ovarian Insufficiency, Premature Menopause, Metabolic Complications, Endothelial Function (FMD), Estrogen Replacement Therapy
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
30 Years to 40 Years · Female only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Nov 1, 2026, 1:44 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Treatment of Menorrhagia in Women With Thrombocytopenia Using Platelets or Platelets and Hormones

NCT00556400
View directory record Official record
Conditions
Aplastic Anemia, Menorrhagia, Amenorrhea
Interventions
Lo-Ovral Oral Contraceptive Pills, Placebo - sugar pill
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 55 Years · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 19, 2013 · Synced Nov 1, 2026, 1:44 AM EDT
Terminated Not applicable Interventional

Text-message Reminders to Increase Rates of Postpartum Diabetes Screening in Women With Gestational Diabetes

NCT02013557
View directory record Official record
Conditions
Diabetes, Gestational
Interventions
Text-message reminder
Behavioral
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older · Female only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 6, 2016 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Not applicable Interventional

Refining Novel Culturally Tailored Behavioral Weight Loss Treatment Components for Sexual Minority Women With Obesity

NCT05036187
View directory record Official record
Conditions
Obesity
Interventions
Behavioral Weight Loss Intervention, Minority Stress Intervention, Negative Body Image Intervention, Social Support Intervention
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Nov 1, 2026, 1:44 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Single Dose Truvada in HIV-negative Men and Women

NCT01326221
View directory record Official record
Conditions
Pharmacokinetic Study in Healthy Volunteers
Interventions
tenofovir + emtricitabine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 49 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Phase 1 Interventional

Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

NCT02167958
View directory record Official record
Conditions
Leukemia, MDS, Myelofibrosis, Lymphoma
Interventions
Fludarabine, Cyclophosphamide, Mesna, Total Body Irradiation, Hematopoietic stem cell infusion, Tacrolimus, Mycophenolate, G-CSF
Drug · Radiation · Other
Lead sponsor
Rafic Farah, MD
Other
Eligibility
18 Years to 70 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Phase 4 Interventional

Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45

NCT06173661
View directory record Official record
Conditions
Migraine, Menstrual Migraine, Menstrually Related Migraine
Interventions
Fremanezumab, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Nov 1, 2026, 1:44 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women

NCT02937766
View directory record Official record
Conditions
Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women
Interventions
Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Nov 1, 2026, 1:44 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

NCT03304080
View directory record Official record
Conditions
Breast Neoplasms, Breast Diseases
Interventions
Anastrozole, Palbociclib, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 1, 2026, 1:44 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Sex Differences in Myocardial Steatosis Induced Left Ventricular Dysfunction

NCT04671966
View directory record Official record
Conditions
Heart Diseases, Left Ventricular Dysfunction
Interventions
Estradiol patch, Cetrotide, Fasting, Lower Body Negative Pressure
Drug · Other
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 30 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis

NCT01044498
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tocilizumab, Ortho-Novum® 1/35
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 44 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
6
States / cities
Little Rock, Arkansas • Beverly Hills, California • Ormond Beach, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2013 · Synced Nov 1, 2026, 1:44 AM EDT
Terminated Phase 1 Interventional

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

NCT06351332
View directory record Official record
Conditions
Breast Cancer, Breast Cancer Female, Triple Negative Breast Cancer, Hormone Receptor Negative Malignant Tumor Breast Triple, HER2-negative Breast Cancer
Interventions
Azenosertib, Carboplatin, Pembrolizumab
Drug
Lead sponsor
Filipa Lynce, MD
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Ascending and Multiple Dose Study to Evaluate Safety, Tolerability, and PK of MYMD1 in Healthy Male and Female Adult Subjects

NCT05077865
View directory record Official record
Conditions
Hashimoto Disease
Interventions
MYMD-1, Placebo
Drug
Lead sponsor
TNF Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Clearwater, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Nov 1, 2026, 1:44 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

NCT03584009
View directory record Official record
Conditions
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
Venetoclax, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Evaluating the Efficacy and Safety of Omnilux Clear on Mitigating Mild to Moderate Acne

NCT06936332
View directory record Official record
Conditions
Acne
Interventions
Omnilux Clear Light Emitting Diode Treatment
Device
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Healthy Love Workshop, an HIV Prevention Intervention for African American Women

NCT00362375
View directory record Official record
Conditions
HIV Infections, Sexually Transmitted Infections
Interventions
Healthy Love Workshop, HIV/AIDS 101 Workshop
Behavioral
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older · Female only
Enrollment
313 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 14, 2010 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Phase 2 Interventional Results available

A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer

NCT00728949
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
IMC-A12 (cixutumumab), tamoxifen, Anastrozole, Letrozole, Exemestane, Fulvestrant
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
9
States / cities
Scottsdale, Arizona • Chicago, Illinois • Westwood, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2018 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Staccato Loxapine PK in Smokers and Nonsmokers

NCT00873769
View directory record Official record
Conditions
Smoking, Cigarette
Interventions
Inhaled Loxapine 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
20 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Nov 1, 2026, 1:44 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy Subjects

NCT00699777
View directory record Official record
Conditions
Osteoporosis
Interventions
Risedronate
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 50 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
4
States / cities
Gainesville, Florida • Miramar, Florida • Austin, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Nov 1, 2026, 1:44 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Preventing Alcohol Misuse and Consequences in Vulnerable Women

NCT05010187
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Behavioral: Motivational Interview (MI), Behavioral: Health Coaching (HC)
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
18 Years to 29 Years · Female only
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Nov 1, 2026, 1:44 AM EDT
Recruiting Not applicable Interventional

Preliminary Effectiveness of Enhanced Text Message + Incentives

NCT07420621
View directory record Official record
Conditions
Smoking Cessation, Pregnancy
Interventions
Text Messages, Incentives
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 1, 2026, 1:44 AM EDT